Age and estimated glomerular filtration rate (eGFR) by the CKD stage for adult Fabry patients
| . | All . | Stage 1 . | Stage 2 . | Stage 3 . | Stage 4/5 . |
|---|---|---|---|---|---|
| n (%) | 1262 | 582 | 425 | 155 | 100 |
| Males (%) | 585 (100) | 275 (47) | 144 (25) | 88 (15) | 78 (13) |
| Females (%) | 677 (100) | 307 (45) | 281 (42) | 67 (10) | 22 (3) |
| Age (years) | |||||
| Males | 30.2 ± 9.2 (18–68) | 42.1 ± 9.8 (19–66) | 45.6 ± 10.3 (20–72) | 43.8 ± 11.6 (21–79) | |
| Females | 35.8 ± 11.0 (18–70) | 46.8 ± 12.6 (18–83) | 56.5 ± 11.1 (24–82) | 46.6 ± 12.3 (20–74) | |
| eGFR (ml/min/1.73 m 2 ) | |||||
| Males | 116 ± 23.7 | 76 ± 8.8 | 46 ± 8.6 | 17 ± 7.8 | |
| Females | 108 ± 16.3 | 77 ± 8.1 | 51 ± 8.0 | 16 ± 8.5 |
| . | All . | Stage 1 . | Stage 2 . | Stage 3 . | Stage 4/5 . |
|---|---|---|---|---|---|
| n (%) | 1262 | 582 | 425 | 155 | 100 |
| Males (%) | 585 (100) | 275 (47) | 144 (25) | 88 (15) | 78 (13) |
| Females (%) | 677 (100) | 307 (45) | 281 (42) | 67 (10) | 22 (3) |
| Age (years) | |||||
| Males | 30.2 ± 9.2 (18–68) | 42.1 ± 9.8 (19–66) | 45.6 ± 10.3 (20–72) | 43.8 ± 11.6 (21–79) | |
| Females | 35.8 ± 11.0 (18–70) | 46.8 ± 12.6 (18–83) | 56.5 ± 11.1 (24–82) | 46.6 ± 12.3 (20–74) | |
| eGFR (ml/min/1.73 m 2 ) | |||||
| Males | 116 ± 23.7 | 76 ± 8.8 | 46 ± 8.6 | 17 ± 7.8 | |
| Females | 108 ± 16.3 | 77 ± 8.1 | 51 ± 8.0 | 16 ± 8.5 |
Age is given as mean ± SD (range); eGFR is given as mean ± SD.
Age and estimated glomerular filtration rate (eGFR) by the CKD stage for adult Fabry patients
| . | All . | Stage 1 . | Stage 2 . | Stage 3 . | Stage 4/5 . |
|---|---|---|---|---|---|
| n (%) | 1262 | 582 | 425 | 155 | 100 |
| Males (%) | 585 (100) | 275 (47) | 144 (25) | 88 (15) | 78 (13) |
| Females (%) | 677 (100) | 307 (45) | 281 (42) | 67 (10) | 22 (3) |
| Age (years) | |||||
| Males | 30.2 ± 9.2 (18–68) | 42.1 ± 9.8 (19–66) | 45.6 ± 10.3 (20–72) | 43.8 ± 11.6 (21–79) | |
| Females | 35.8 ± 11.0 (18–70) | 46.8 ± 12.6 (18–83) | 56.5 ± 11.1 (24–82) | 46.6 ± 12.3 (20–74) | |
| eGFR (ml/min/1.73 m 2 ) | |||||
| Males | 116 ± 23.7 | 76 ± 8.8 | 46 ± 8.6 | 17 ± 7.8 | |
| Females | 108 ± 16.3 | 77 ± 8.1 | 51 ± 8.0 | 16 ± 8.5 |
| . | All . | Stage 1 . | Stage 2 . | Stage 3 . | Stage 4/5 . |
|---|---|---|---|---|---|
| n (%) | 1262 | 582 | 425 | 155 | 100 |
| Males (%) | 585 (100) | 275 (47) | 144 (25) | 88 (15) | 78 (13) |
| Females (%) | 677 (100) | 307 (45) | 281 (42) | 67 (10) | 22 (3) |
| Age (years) | |||||
| Males | 30.2 ± 9.2 (18–68) | 42.1 ± 9.8 (19–66) | 45.6 ± 10.3 (20–72) | 43.8 ± 11.6 (21–79) | |
| Females | 35.8 ± 11.0 (18–70) | 46.8 ± 12.6 (18–83) | 56.5 ± 11.1 (24–82) | 46.6 ± 12.3 (20–74) | |
| eGFR (ml/min/1.73 m 2 ) | |||||
| Males | 116 ± 23.7 | 76 ± 8.8 | 46 ± 8.6 | 17 ± 7.8 | |
| Females | 108 ± 16.3 | 77 ± 8.1 | 51 ± 8.0 | 16 ± 8.5 |
Age is given as mean ± SD (range); eGFR is given as mean ± SD.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
